Delwail V, Bataille B
Service d'Hématologie et Oncologie Médicale, CHU, Poitiers.
Neurochirurgie. 1997;43(6):380-4.
Effective treatment in primary central nervous system lymphoma remains elusive. Usually high dose methotrexate and/or cytosine arabinoside may improve survival. We report the results of multimodality therapy in 248 patients (SFNC series). The addition of chemotherapy to radiation therapy and high dose methotrexate increased the duration of survival. We demonstrate that the use of anthracyclines in addition to radiation therapy had a significantly favorable impact on survival which is not reported in the literature. Survival was not longer in patients receiving intrathecal chemotherapy. The efficacy of chemotherapy alone has not been clearly defined.
原发性中枢神经系统淋巴瘤的有效治疗方法仍难以捉摸。通常,高剂量甲氨蝶呤和/或阿糖胞苷可能会提高生存率。我们报告了248例患者(SFNC系列)多模式治疗的结果。在放射治疗和高剂量甲氨蝶呤基础上加用化疗可延长生存期。我们证明,在放射治疗基础上加用蒽环类药物对生存率有显著的有利影响,这在文献中尚未见报道。接受鞘内化疗的患者生存期并未延长。单纯化疗的疗效尚未明确界定。